Asia Pacific
Refine Search
Biotechnology
South Korea’s Alteogen has signed an exclusive licensing agreement with Japanese pharmaceutical company Daiichi Sankyo for its human hyaluronidase, ALT-B4. 9 November 2024
Pharmaceutical
Pfizer has announced plans to invest $1 billion in China by 2030, targeting accelerated innovation, diagnostics improvements, and support for the local biotechnology sector. 8 November 2024
Biotechnology
Japanese ophthalmology company Santen Pharmaceutical has crossed the East China Sea in its latest collaboration, announced on Thursday. 8 November 2024
Pharmaceutical
UK pharma major AstraZeneca, which has invested heavily in China, hosted a sell-side analyst call on Wednesday (November 6) to discuss the recent media reports about ongoing investigations in China. 7 November 2024
Pharmaceutical
Photocure, a Norway-based bladder cancer-focused company, has announced that Jiangsu Yahong Meditech, the parent company of its partner Asieris Pharmaceuticals, has received marketing authorization for Hexvix (hexaminolevulinate) in China. 5 November 2024
Biotechnology
Japan’s Nxera Pharma – formerly known as Sosei – and Antiverse, a UK techbio company designing antibodies for challenging targets, have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs). 5 November 2024
Pharmaceutical
Denmark’s privately-held dermatology specialist LEO Pharma and Japan’s Kyowa Kirin have revealed that they will terminate the distribution and co-promotion agreement for the psoriasis vulgaris treatment Dovobet Ointment, Gel, and Foam (calcipotriol hydrate / betamethasone dipropionate) in Japan on December 31, 2024. 1 November 2024
Biotechnology
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved the medicine sugemalimab (trade name Eqjubi) to treat adult patients with a type of cancer called non-small cell lung cancer (NSCLC ). 31 October 2024
Pharmaceutical
Japanese pharma major Takeda today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. 31 October 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
Takeda has release positive interim results from a Phase III-enabling proof-of-concept study for mezagitamab (TAK-079), a potential best-in-class anti-CD83 monoclonal antibody, in patients with primary immunoglobulin A nephropathy (IgAN). 29 October 2024
Biotechnology
South Korea’s GemVax & KAEL has reported positive top-line results from a Phase IIa trial of GV1001, for progressive supranuclear palsy (PSP). 29 October 2024
Pharmaceutical
Corxel Pharmaceuticals and LENZ Therapeutics have reported encouraging topline results from a Phase III trial in China testing LENZ’s aceclidine-based eye drop, LNZ100. 29 October 2024
Pharmaceutical
Japanese drugmaker Shionogi saw its shares rise 2.3% to 2,173 yen today after it released positive research findings. 29 October 2024
Biotechnology
Yongyin-based biopharma company GC Biopharma has announced a partnership with Novelty Nobility for the joint development of a new treatment for geographic atrophy (GA). 28 October 2024
Pharmaceutical
Japanese drugmaker Astellas Pharma revealed it has decided to withdraw its marketing authorization application from the European Medicines Agency (EMA) for avacincaptad pegol intravitreal solution (ACP). 28 October 2024
Pharmaceutical
Japanese drugmaker Chugai Pharmaceutical has announced its financial results for the third quarter of fiscal year 2024. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Pharmaceutical
US privately-held drug developer NImmune Biopharma has acquired development and commercialization rights for omilancor in Asia from Sino-American biotech LianBio. 25 October 2024
Biotechnology
Legend Biotech has removed Genscript Biotech as its majority shareholder, in a move coinciding with rising US concerns over Chinese ties within the biotech sector. 24 October 2024
Pharmaceutical
Japanese pharma Daiichi Sankyo has denied that it is negotiating the sale of its subsidiary, Daiichi Sankyo Healthcare, despite media reports that talks are underway. 24 May 2019
Biotechnology
China must take measures to largely improve its clinical data quality to be a competitive player in the global biotech market, said speakers at China’s recent clinical development summit held in Shanghai, reports The Pharma Letter’s local correspondent Wang Fangqing. 24 May 2019
Pharmaceutical
GlaxoSmithKline today announced that China’s National Medical Products Administration (NMPA) has approved Shingrix for the prevention of shingles (herpes zoster) in adults aged 50 years or older. 23 May 2019
Pharmaceutical
A new study on the Chinese pharmaceutical market, the CPhI Annual Report, highlights an increase in API manufacturing, innovation, competitiveness and finished product manufacturing. 23 May 2019
Biotechnology
Tokyo-based Chugai Pharmaceutical is to close two research centers and transfer their functions to a new facility that it will build in Yokohama. 23 May 2019
Biotechnology
Less than a year after Japanese drugmaker Takeda’s Entyvio was approved in the company’s home country to treat ulcerative colitis, a further indication for the drug has been authorized. 22 May 2019
Biotechnology
As China is becoming an incubator for an increasing number of innovative biotech startups, multinationals are actively seeking potential novel assets to enrich their global pipelines, said speakers at the ChinaBio forum held recently in Shanghai, reports The Pharma Letter’s local correspondent Wang Fangqing. 20 May 2019
Biotechnology
A draft issued on March 29 by China’s National Health Commission (CNHC), which regulates hospitals in China, allows qualified 3 Jia ( meaning top-level) public hospitals to develop and commercialize somatic cell therapies within their own hospitals. 17 May 2019
Biotechnology
Chuikyo, Japan’s Central Social Insurance Medical Council, on May 15 approved the listing of Swiss pharma giant Novartis’ CAR-T cell therapy Kymriah (tisagenlecleucel) on May 22, with a National Health Insurance (NHI) price tag of some 33.5 million yen ($305,800), according to media reports. 15 May 2019
Pharmaceutical
Japanese drugmaker Shionogi says it has prepared and released its “Shionogi AMR Position Paper.” 13 May 2019
Biotechnology
Companies developing cell therapies for heart failure, compounds to treat obesity and peptide vaccines for cancer were among those that presented their pitches as part of a Japanese program to boost start-ups in the pharmaceutical sector. 9 May 2019
Biosimilars
Swiss pharma giant Roche’s non-Hodgkin’s lymphoma treatment MabThera (rituximab) is facing a strong rival in China - its biosimilar version Hanlikang from Fosun Pharma’s biotech arm Henlius. 7 May 2019
Pharmaceutical
Researchers at the Beijing Institute of Genomics (BIG) have been to Fiocruz for the Brazil-China seminar on Bioinformatics, Big Data and Precision Medicine. 7 May 2019
Biosimilars
An executive and another employee at Korean biosimilars powerhouse Samsung Bioepis have been arrested, according to The Financial Times and other sources. 30 April 2019
Pharmaceutical
US pharma major Eli Lilly has agreed to sell Chinese rights to two legacy antibiotic medicines, Ceclor (cefaclor) and Vancocin (vancomycin), as well as a manufacturing facility in Suzhou. 23 April 2019
Biotechnology
Hutchinson China MedTech Limited has never downplayed the extent of its ambition to put Chinese drug development on the map, so clearly it has not held back with the hyperbole on announcing its upcoming global offering on the Stock Exchange of Hong Kong (SEHK). 15 April 2019
Pharmaceutical
Chinese drugmaker Hansoh Pharmaceutical Group has re-filed its application for an initial public offering (IPO) in Hong Kong, according to sources quoted by Reuters. 15 April 2019
Pharmaceutical
Daiichi Sankyo says that valemetostat (DS-3201), an investigational and potential first-in-class EZH1/2 dual inhibitor, has received Sakigake designation from the MHLW. 9 April 2019
Biotechnology
China’s biopharma start up Ascentage Pharma has entered into a strategic collaboration with Shanghai Junshi Biosciences to explore the synergies of Ascentage's inhibitor of apoptosis proteins (IAP) inhibitor APG-1387, and Junshi Biosciences' anti-PD-1 therapy toripalimab in clinical trials in solid and hematological tumors in China. 9 April 2019
Biotechnology
Shares in Japanese oncology specialist Oncolys Biopharma closed 18% up on Monday after the announcement of a deal with Chugai Pharmaceutical, part of Swiss pharma giant Roche. 8 April 2019
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze